Abon Pharmaceuticals

What Abon Pharmaceuticals does

Abon Pharmaceuticals, LLC is a privately held specialty pharmaceutical company founded in 2009 and headquartered in Chestnut Ridge, New York. The company develops complex generics and proprietary pharmaceutical products across injectable, oral, and other dosage forms with high barriers to entry, anchored by FDA-approved generic versions of Clofarabine Injection (2017), Atovaquone Oral Suspension (2021/2023), and Sucralfate Oral Suspension (2024). Its underlying technology platform spans parenteral drug delivery (long-acting injectables, biodegradable microspheres, nanotube depots, lyophilized powders), micro- and nano-technology (high-pressure homogenization, microfluidization), oral drug delivery systems (sustained/modified release, osmotic, gastroretentive, pulsatile, transmucosal), and a full suite of pre-formulation, analytical, and pharmacokinetic services, supported by four granted US patents and several pending filings.

The company monetizes through one-time licensing/royalty arrangements with strategic marketing partners, transaction fees tied to ANDA filings (including paragraph IV certifications eligible for 180-day exclusivity), and direct U.S. distribution of approved generics. Clofarabine Injection is commercialized via a marketing partnership with Fresenius Kabi, while oral suspension products are distributed directly domestically; the company is also actively seeking global partners for manufacturing and distribution of proprietary long-acting injectable technologies and 505(b)(2) products. Its customer base consists of healthcare providers and institutions (hospitals, clinics) requiring complex generic medications, with an additional B2B customer segment of pharmaceutical companies seeking manufacturing and partnership opportunities for proprietary drug delivery platforms.

Name

Abon Pharmaceuticals

Legal name

Abon Pharmaceuticals, LLC

Website

https://abonpharma.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Abon Pharmaceuticals is a privately held specialty pharmaceutical company that develops and commercializes complex generic and proprietary 505(b)(2) drug products across injectable and oral dosage forms. Founded in 2009 and based in Chestnut Ridge, NY, it serves healthcare institutions and partners with firms like Fresenius Kabi.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

akta.pro secondary industries

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Complex generic pharmaceuticals
• Specialty injectable drugs
• Oral suspension generics
• Long-acting injectables
• 505(b)(2) drug development

Headquarters

HQ city

Northvale

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Infrastructure, Personnel, Supply Chain, Operations

Revenue model

1. Generic Pharmaceutical Sales: Revenue from FDA-approved generic pharmaceutical products including sucralfate oral suspension, atovaquone oral suspension, and clofarabine injection. Sales through marketing partners like Fresenius Kabi.
2. ANDA Filing and Approval: Abbreviated New Drug Application (ANDA) filings with paragraph IV certifications that may entitle 180 days of generic market exclusivity upon approval.
3. Proprietary Product Development: Development and potential commercialization of proprietary products through 505(b)(2) pathway, including long-acting injectables and novel drug delivery systems.
4. Partnership and Licensing Deals: Revenue from seeking global partners for manufacturing and distribution of proprietary technologies and complex generics in the Long-Acting Injectable space.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels3 records

Core offering

Abon Pharmaceuticals is a specialty pharmaceutical company that develops and commercializes complex generics and 505(b)(2) proprietary products across injectable, oral, and other dosage forms with high barriers to entry. Its commercial portfolio includes FDA-approved generic equivalents (Sucralfate Oral Suspension, Atovaquone Oral Suspension, and Clofarabine Injection), while its pipeline covers long-acting injectables, extended-release oral dosage forms, oral transmucosal systems, and intravenous delivery systems. The company operates integrated pre-formulation, formulation, analytical, pharmacokinetic, GMP manufacturing, and pilot plant capabilities to advance complex dosage forms.

Product overview

Abon Pharmaceuticals is a specialty pharmaceutical company focused on complex generics and proprietary products across injectable, oral, and other dosage forms with high barriers to entry. The company operates as an integrated pharmaceutical development organization with four core R&D service modules: Pre-formulation, Formulation & Process Development, Analytical Services, and Pharmacokinetics. The commercial product portfolio includes FDA-approved generic drugs: Sucralfate Oral Suspension (Carafate® generic), Atovaquone Oral Suspension (Mepron® generic), and Clofarabine Injection (Clolar® generic). The pipeline encompasses 505(b)(2) proprietary products including extended-release oral dosage forms, oral transmucosal formulations for hypogonadism and HRT, long-acting injectable technologies, and intravenous delivery systems. Long-acting injectable generics in development include polypeptides for cancer treatment and biodegradable microspheres for psychotherapeutic drugs and acromegaly.

Differentiator

Problem solved

Functional benefit

Products and services

• Sucralfate Oral Suspension, 1 g/10 ml FDA-approved complex generic version of Carafate® (sucralfate) Oral Suspension, 1 g/10 ml for oral administration, targeting hospitals, clinics, and institutional healthcare buyers needing complex generic alternatives.
• Atovaquone Oral Suspension, 750 mg/5 ml FDA-approved generic version of Mepron® (atovaquone) Oral Suspension, 750 mg/5 ml for oral administration, targeted at healthcare providers and institutional buyers seeking lower-cost specialty oral alternatives.
• Clofarabine Injection, 20 mg/20 mL (1 mg/mL) FDA-approved generic anticancer injectable bioequivalent to Clolar® Injection, supplied in a single-use vial and commercialized through marketing partner Fresenius Kabi for institutional oncology use.
• Extended-release oral dosage form for poorly soluble amine drugs (505(b)(2) pipeline) 505(b)(2) proprietary extended-release oral dosage form technology for poorly soluble amine drugs, pursued for global partnership-based commercialization.
• Oral transmucosal dosage form for Hypogonadism (505(b)(2) pipeline) 505(b)(2) proprietary oral transmucosal dosage form offering superior patient compliance, safety and efficacy for the treatment of Hypogonadism.
• Oral transmucosal dosage form for Hormone Replacement Therapy (505(b)(2) pipeline) 505(b)(2) proprietary oral transmucosal dosage form offering superior patient compliance, safety and efficacy for Hormone Replacement Therapy.
• Long Acting Injection from Solution for psychotherapeutic drug (505(b)(2) pipeline) 505(b)(2) proprietary long-acting injection from solution formulation for a psychotherapeutic drug, targeted at global pharmaceutical partners.
• Long Acting Injection from Suspension for psychotherapeutic drug (505(b)(2) pipeline) 505(b)(2) proprietary long-acting injection from suspension formulation for a psychotherapeutic drug, targeted at global pharmaceutical partners.
• Intravenous Delivery System for chemotherapy drugs (505(b)(2) pipeline) 505(b)(2) proprietary intravenous delivery system for chemotherapy drugs, targeted at global pharmaceutical partners.
• Improved delivery system for glucosylceramide synthase inhibitor (505(b)(2) pipeline) 505(b)(2) proprietary improved delivery system for an inhibitor of glucosylceramide synthase to overcome metabolic variability, targeted at global pharmaceutical partners.
• Long-acting injectable polypeptide for cancer treatment (generic pipeline) Long-acting injectable generic pipeline product comprising a polypeptide for cancer treatment, targeted at global pharmaceutical partners.
• Biodegradable microsphere for psychotherapeutic drug (long-acting injectable generic pipeline) Long-acting injectable generic pipeline product using a biodegradable microsphere formulation for a psychotherapeutic drug, targeted at global pharmaceutical partners.
• Biodegradable microsphere for acromegaly and certain cancers (long-acting injectable generic pipeline) Long-acting injectable generic pipeline product using a biodegradable microsphere formulation for acromegaly and certain cancers, targeted at global pharmaceutical partners.
• Microparticle suspension for psychotherapeutic drug (long-acting injectable generic pipeline) Long-acting injectable generic pipeline product using a microparticle suspension formulation for a psychotherapeutic drug, targeted at global pharmaceutical partners.
• Pre-formulation Services R&D service module delivering characterization studies (solid state, thermal, visco-elastic, powder, compatibility, solubility, particle size) supporting complex generic and proprietary product development.
• Formulation & Process Development Services R&D service module covering parenteral dosage forms (long-acting injectables, oil-based preparations, aqueous micro-particle suspensions, lyophilized powder, biodegradable microspheres, nanotube depots), micro/nanotechnology, and oral dosage forms (immediate release, sustained/modified release, multi-layered tablets, osmotic tablets, gastroretentive, pulsatile, transmucosal).
• Analytical Services R&D service module providing physical and chemical characterization, analytical method development and validation (HPLC, GC), dissolution methods, polymer characterization, peptide characterization (NMR, IR, Mass spec), and in-vitro bioequivalence studies (BSA binding, pepsin inhibition, bile salts binding).
• Pharmacokinetics Services R&D service module using statistical design and mathematical modeling with pharmacokinetic principles to develop products with predictable outcomes and higher assurance in bio/clinical study success.

Quantifiable outcome

• FDA approval of ANDA for generic version of Carafate (sucralfate) Oral Suspension on March 18, 2024, with U.S. market annual sales of approximately $146 million
• +2 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature12 records

Partnerships

One partnership is on record.

• Fresenius KabicoreChannel Partner/ Reseller/ Distributor · 9 May 2017Fresenius Kabi serves as the marketing partner for Abon's Clofarabine Injection, a generic version of Clolar Injection. Abon received FDA approval for this anticancer injectable product and prepared to launch it with Fresenius Kabi handling marketing and distribution.

Scale indicators8 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Hikma Pharmaceuticals: Specialty generic pharmaceutical company with a strong injectable franchise and complex generics portfolio, directly comparable to Abon in targeting hard-to-formulate molecules and operating partner-driven commercialization models.
• Lannett Company: US-focused generic pharmaceutical manufacturer with an oral solids and specialty injectable portfolio; comparable to Abon as a smaller-cap US specialty generic operator pursuing complex generic approvals.
• Amneal Pharmaceuticals: Specialty generics and complex dosage-form developer with injectable, oral, and 505(b)(2) capabilities; closely comparable to Abon in pursuing complex generics and proprietary drug delivery products.

Broad incumbents

• Endo International: Specialty pharmaceutical company with a generics segment (Par Pharmaceutical) and injectable capabilities; broader portfolio than Abon but operates in overlapping complex generic and injectable categories.
• Dr. Reddy's Laboratories: Global generic pharmaceutical major with strong injectable and complex generics businesses; comparable to Abon in targeting paragraph IV generic approvals and complex dosage forms but at materially greater scale.
• Apotex: Canadian-headquartered generic pharmaceutical manufacturer with a broad complex generics portfolio; comparable to Abon as a privately-held, founder-led generic operator pursuing differentiated generic approvals.
• Teva Pharmaceutical Industries: Largest global generic pharmaceutical company that acquired Barr Pharmaceuticals (Abon founders' former company) in 2008; relevant as the dominant incumbent in the same competitive set and acquirer of Abon's leadership alumni.
• Sun Pharmaceutical Industries: Global specialty generic pharmaceutical company with complex generics, injectables, and proprietary drug delivery capabilities; comparable to Abon in dosage-form complexity but at significantly greater commercial scale.

Regional players

• Aurobindo Pharma: India-based global generic pharmaceutical manufacturer with growing US complex generics and injectable presence; comparable in complex generics strategy, though primarily operating from non-US geographies.

Emerging players

• Inotiv: Specialty pharmaceutical and drug delivery development services company; relevant adjacent comparable for Abon's R&D service modules (pre-formulation, formulation, analytical, pharmacokinetics) where outsourced development capability is the offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abon Pharmaceuticals